Stock code: 300759.SZ

Stock code: 3759.HK

2026

Interim Results

康龙化成
PHARMARON

August 2026

Disclaimer

The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law, and the recipients into whose possession this Document comes should inform themselves about, and observe such restrictions. By accessing this Document, you are agreeing (i) that you have read and agree to comply with the contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.

This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and nothing contained herein shall form the basis of any investment decision, contract or commitment whatsoever. This Document contains no information or material which may result in it being deemed (1) to be an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under the laws of any state of the United States. This Document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.

This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, PRC, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction's securities laws. Upon request, the recipient will promptly return this Document and any other written information made available in the presentation, without retaining any copies.

This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation, warranty or undertaking, express or implied, is given and, so far as is permitted by law, no responsibility or liability is accepted by any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this Document or its contents. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects", “intends”, “plans to” and "anticipates" and words of similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any assumptions, projections, targets, estimates, forecasts or any forward-looking statements contained in this Document. Each of the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.

In furnishing this Document, the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may become apparent.

Contents

CONTENT

2Q2026 Revenue and Adjusted Net Profit Growth Remain Robust

RMB mm	2Q2026	1Q2026	QoQ	2Q2025	YoY
Revenue	4,017	3,578	12.3%	3,342	20.2%
Net Profit	415	335	23.7%	396	4.8%
Non-IFRS Adjusted Net Profit	503	406	23.8%	406	23.8%

- Revenue & Non-IFRS adjusted net profit growth both accelerated in 2Q2026 compared to 1Q2026

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

1H2026 Financials & 2026 Outlook

康龙化成 PHARMARON

RMB mm	1H2026	1H2025	YoY
Revenue	7,595	6,441	17.9%
Net Profit	750	701	7.0%
Non-IFRS Net Profit	909	756	20.3%

- **New POs:** new POs increased by 30%+ YoY
- **MNC Customers:** revenue from TOP20 Pharmas increased by 32.0% YoY
- **Guidance: raise 2026 revenue growth guidance to 15-20%**

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

Global Platform & Customers

470+ new customers in 1H2026, 3,400+ active customers TTM, incl. all TOP20 global pharmas

28 R&D & Mfg. facilities in CN, UK & US. 27,316 emps., incl. 1,700+ overseas emps. 24,953 scientists & technicians, representing 91%+ of total emps.

Enabling customers with cutting-edge technologies: strengthen lab/CDMO capabilities for new modalities; enhance NAM platform; advance AI & automation adoption; explore quantum computing for CADD with Logic Qubit & ZJU.; explore embodied intelligent robots for R&D and Mfg. workflows with AI² Robotics

Rich Pipeline to Fuel Future Growth

Discovery projects: 811 drug discovery projects

SM CDMO projects: 45 in PPQ & commercial, 51 in PhIII, 238 in PhI/II, 448 in preclinical

Clinical CRO projects: 1,357 CRO projects, incl. 132 in PhIII, 589 in PhI/II, and 636 other projects (incl. PhIV, IIT &RWS)

SMO projects: 2,200+ projects, CRC team covers 700+ hospitals & clinical trial centers in 150+ cities

1H2026 Revenue Compositions

Segments | **Revenue Composition**



Global Customers | **Revenue Composition**

Customers from NA Revenue Grew **14.8%**

Customers from EU Revenue Grew **6.0%**

Customers from Mainland CN Revenue Grew **41.9%**



China/Overseas Entities | **Revenue Composition**

China Entities Revenue Grew **20.7%**

Overseas Subsidiaries Revenue Declined **1.9%**



Diversified Customer Base | **Revenue Composition**

TOP20 Pharmas Revenue Grew **32.0%**

Other Customers Revenue Grew **14.8%**



ESG Updates

ESG Ratings	ISO Cert. & UNGC	Sustainable Development
2025 MSCI ESG Rating **AA**	• Obtained expanded certifications for the ISO 27001, ISO 14001, ISO 45001 & ISO 22301	• Included in S&P Global Sustainability Yearbook • Awarded the title of "Industry Mover" by S&P Global
SUSTAINALYTICS 2025 Low Risk Company; 2026 Industry ESG Leader, Regional ESG Leader, Global ESG Leader	Joined in the United Nations Global Compact (UNGC)	2025 EcoVadis Silver Prize

CONTENT

Accelerating Platform Integration to Strengthen New Modality Service Capabilities

The complexity of drug candidates is rising, while the distinctions between molecular modalities are fading

Small Molecule

Greater complexity & developability challenges

Peptide & Oligo

Long-chain synthesis + chemical modification + delivery

Biologic & Bioconjugate

Antibody / peptide + Linker + small molecule

Cell & Gene Therapy

Cell therapy / gene vector + delivery & release

As conjugation, modification, & delivery technologies converge, a single platform cannot meet the R&D needs

Accelerating CRO & CDMO platform integration to address R&D demands

Synergized Lab Services

Synergizing synthesis, analytical, & bioassay platforms

CDMO Platform

Integrated PD & commercial-scale manufacturing

Technology Integration

Integration of small molecule & new modality capabilities

Integrated Services

End-to-end integrated delivery for enhanced efficiency

Synergies Across Three Segments to Accelerate R&D of Multi-Modality Therapeutics

	Laboratory Services		CDMO Services	Clinical Dev. Services
	Discovery (PCC)	**Preclinical (IND)**	**Clinical (NDA/BLA)**	**Commercial**
Small Molecule (Incl. Peptide)	Laboratory Chemistry *In vitro* Biology *In vivo* Pharmacology DMPK Exploratory Tox	Early Dev. of DS & DP *In vitro* Biology *In vivo* Pharmacology DMPK Safety Assessment	DS & DP Production PhI–III Clinical Dev. Clinical 14C-ADME PK/Bioanalytical/Biomarkers	DS & DP Production PhIV & Post-mkt.
Biologic & Bioconjugate	Biologics Discovery Protein Prod. & Char. *In vitro* Biology *In vivo* Pharmacology HP/PD Immunogenicity/Toxicity	Developability Assess. Proc. Scale-up & Prod. HP/PD Immunogenicity Safety Assessment	DS & DP Production Immunogenicity PhI–III Clinical Dev. PK/Bioanalytical/Biomarkers	DS & DP Production PhIV & Post-mkt.
CGT (Incl. oligo)	*In vitro* Biology *In vivo* Pharmacology Candidate Cloning HP/PD Immunogenicity Exploratory Tox	Early Proc./Form. Dev. Viral Shedding Analysis *In vitro* Potency PK/PD/Tissue Distribution Immunogenicity Safety Assessment	Gene Therapy Mfg. Viral Shedding Analysis *In vitro* Release Test Immunogenicity PhI–III Clinical Dev. PK/Bioanalytical/Biomarkers	Gene Therapy Mfg. *In vitro* Release Test PhIV & Post-mkt.

Large-scale production capacities for peptides, oligonucleotides, and bioconjugates are currently under construction

Laboratory Services

RMB mm	2Q2026	1Q2026	QoQ	2Q2025	YoY	1H2026	1H2025	YoY
Revenue	2,430	2,204	10.2%	2,132	13.9%	4,634	4,075	13.7%
GPM	39.8%	41.7%	-1.9pct	42.0%	-2.2pct	40.7%	42.4%	-1.7pct

- Solid growth of lab chemistry services. Strong growth of bioscience services, especially new modality business. Bioscience services accounted for 60%+ of the segment's total revenue
- New POs grew by 20%+ YoY
- Participated in 811 drug discovery projects
- Continuing capacity expansion to support mid-to-long-term demand, with Beijing Campus III coming online and Ningbo Campuses III & IV on track

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

CDMO Services

RMB mm	2Q2026	1Q2026	QoQ	2Q2025	YoY	1H2026	1H2025	YoY
Revenue	1,012	872	15.9%	712	42.0%	1,884	1,419	32.8%
GPM	26.8%	24.1%	2.7pct	23.4%	3.4pct	25.6%	22.9%	2.7pct

- Strong synergies: 85%+ of CDMO revenue came from customers of lab services
- New POs grew by 50%+ YoY. Significant progress in large-scale SM CDMO services, with more projects expected to be delivered in 2H2026
- Milestones in commercial manufacturing: (1) signed a commercial manufacturing agreement with an MNC for an oral GLP-1 DP. (2) API facility in Ningbo passed its first NMPA PAI
- Accelerating capacity expansion of SM CDMO services in Shaoxing & Hangzhou. Continuing to strengthen integrated CDMO capabilities for peptides & bioconjugates

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

Small Molecule CDMO Projects Continued to Advance to Late Stage



Clinical Development Services

RMB mm	2Q2026	1Q2026	QoQ	2Q2025	YoY	1H2026	1H2025	YoY
Revenue	568	500	13.7%	492	15.5%	1,069	939	13.8%
GPM	12.1%	7.1%	5.0pct	12.8%	-0.7pct	9.8%	12.3%	-2.5pct

- New POs grew by 30%+ YoY
- 1,357 CRO projects, incl. 132 PhIII trials, 589 PhI/II trials & 636 other clinical trials
- 2,200+ SMO projects. CRC team covered 700+ hospitals & clinical trial centers in 150+ cities
- Continuously improving productivities through refined operations and the adoption of digital & AI-enabled tools
- Controlling subsidiary Aistarfish achieved meaningful scale in real-world patient management & RWS service orders, and partnered with top-tier domestic hospitals for RWS collaborations

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

CONTENT

1H2026 Expenses for the Period

Selling and Distribution Expenses as % of Total Revenue



Administrative Expenses as % of Total Revenue (1)



R&D Costs as % of Total Revenue



Net Finance Costs as % of Total Revenue (2)



1. Excluding share-based compensation expenses and one-off reorganization-related expenses recognized in administrative expenses
2. Net finance costs including interest expenses on bank borrowings and lease liabilities, interest income and bank wealth management products related gains or losses

Scaling Capacity & Supply to Meet Growing Customer Demand



1H2026 Non-IFRS Adjusted Net Profit

RMB mm	1H2026	1H2025
Net Profit	**750**	**701**
Add:		
Share-based Compensation Expenses	**37**	**26**
Foreign Exchange Related Losses	**104**	**23**
Realized and Unrealized (Gains) /Losses from Equity Investments	**(31)**	**5**
Amortization of Intangible Assets from Acquisitions	**15**	**1**
One-off Reorganization-related Expenses	**34**	**-**
Non-IFRS Adjusted Net Profit	**909**	**756**

Financials are prepared in accordance with IFRS. Data are rounded to the nearest million

CONTENT

2026 Outlook

The evolving healthcare demands and technological innovations will sustain the development of our industry. Global customer demand continue to demonstrate resilience, while demand from China customers is showing signs of recovery

Continue to develop our end-to-end, fully integrated and multiple modalities-capable service platform, commit to the CRDMO business model across the entire drug lifecycle, and deepen the integration of AI & automation across operations to drive sustained growth

Raise 2026 revenue growth guidance to 15-20%

康龙化成
PHARMARON

THANK YOU